Kinetics and metabolite profile of insulin glargine (Lantus®)

被引：0
|
作者：
Kuerzel, GU [1 ]
Sandow, J [1 ]
Seipke, G [1 ]
Lang, AM [1 ]
Mass, J [1 ]
Skrzipczyk, HJ [1 ]
机构：
[1] Aventis Pharma, Frankfurt, Germany
来源：
DIABETOLOGIA | 2001年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
798
引用
收藏
页码：A208 / A208
页数：1
相关论文
共 50 条
  • [41] COST-EFECTIVENESS ANALYSIS OF INSULIN GLARGINE (LANTUS) INITIATION BY PHARMACISTS IN A CANADIAN SETTING: THE RXING STUDY
    Al Hamarneh, Y.
    Sauriol, L.
    Tsuyuki, R.
    Brown, S. T.
    VALUE IN HEALTH, 2014, 17 (03) : A135 - A135
  • [42] Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study
    Christofides, Elena A.
    Puente, Orlando
    Norwood, Paul
    Denham, Douglas
    Maheshwari, Hiralal
    Lillestol, Michael
    Hart, Terence
    Nakhle, Samer
    Chadha, Anurekha
    Fitz-Patrick, David
    Sugimoto, Danny
    Soufer, Joseph
    Young, Douglas
    Warren, Mark
    Huffman, David
    Reed, John
    Bays, Harold
    Arora, Samir
    Rizzardi, Barbara
    Tidman, Raymond
    Rendell, Marc
    Johnson, Kimball A.
    DIABETES OBESITY & METABOLISM, 2024, 26 (06): : 2412 - 2421
  • [43] Treatment Satisfaction in Adults with Type 1 Diabetes Using Meal-time Inhaled Technosphere® Insulin (Afrezza®) in Combination with Insulin Glargine (Lantus®) Versus Insulin Lispro (Humalog®) in Combination with Glargine
    Petrucci, Richard E.
    Peyrot, Mark
    Rubin, Richard R.
    DIABETES, 2011, 60 : A257 - A257
  • [44] Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trial
    Yan, Xiang
    Jiang, Shan
    Lou, Ying
    Zhou, Zhiguang
    DIABETES OBESITY & METABOLISM, 2021, 23 (10): : 2226 - 2233
  • [45] Glycemic Exposure Is Affected Favorably by Inhaled Human Insulin (Exubera) as Compared with Subcutaneous Insulin Glargine (Lantus) in Patients with Type 2 Diabetes
    Hompesch, Marcus
    Kollmeier, Alexa
    Rave, Klaus
    Heinemann, Lutz
    Mitnick, Michael
    Davies, Simon
    Strack, Thomas
    DIABETES TECHNOLOGY & THERAPEUTICS, 2009, 11 (05) : 307 - 313
  • [46] Endocrinological evaluation of dawn phenomenon in patients with diabetes and comparison of insulin glargine U-100 biosimilar (Insulin Glargine BS Injection "Lilly") and glargine U-300 (Lantus XR): a randomized controlled study
    Hasebe, Masanori
    Satoh, Shinobu
    Ito, Kohei
    Tamura, Haruka
    Terauchi, Yasuo
    ENDOCRINE JOURNAL, 2023, 70 (08) : 777 - 786
  • [47] Evaluation of the long-term efficacy of insulin glargine (LANTUS®) in patients with type 1 diabetes in clinical practice
    Schreiber, S
    Russmann, A
    DIABETES, 2003, 52 : A456 - A456
  • [48] Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naive or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study)
    Rosenstock, J.
    Hollander, P.
    Bhargava, A.
    Ilag, L. L.
    Pollom, R. K.
    Zielonka, J. S.
    Huster, W. J.
    Prince, M. J.
    DIABETES OBESITY & METABOLISM, 2015, 17 (08): : 734 - 741
  • [49] Similar Efficacy and Safety of LY2963016 Insulin Glargine and Insulin Glargine (Lantus®) in Patients with T2D in Age Groups (< 65 Yrs,=65 Yrs)
    Pollom, Robyn K.
    Costigan, Timothy
    Lacaya, Lyndon B.
    Ilag, Liza L.
    Hollander, Priscilla A.
    DIABETES, 2016, 65 : A249 - A249
  • [50] Changing from prior premix insulin regimen to insulin glargine in patients with Type 1 diabetes: results from the AT.LANTUS trial
    Conget, I
    Storms, E
    Rodriguez, J
    Leperlier, C
    Davies, M
    Gomis, R
    DIABETOLOGIA, 2004, 47 : A33 - A33
12345